Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V441 in Healthy Infants in Taiwan
NCT00092469Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2002
- Primary completion
- Aug 2003
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, single-arm trial of V441 in diphtheria, Tetanus, pertussis and 3 more, sponsored by Merck & Co. Primary endpoints: Safety and Tolerability at 65 weeks and Immunogenicity at 65 weeks. Started Mar 2002; status: completed.
02
Drugs
V441
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT00092469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092469.